References

Osteoporosis

2022 · External reference

Mortality associated with osteoporosis and pathological fractures in the United States (1999–2020): a multiple-cause-of-death study

10.1186/s13018-024-05068-1 · 2024 · External reference

The epidemiology and pathogenesis of osteoporosis

2020 · External reference

The assessment of fracture risk

10.2106/jbjs.i.00919 · 2010 · External reference

Unresolved reference

External reference

Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society∗ Clinical Practice Guideline

10.1210/jc.2019-00221 · 2019 · External reference

Biosimilars: part 1: proposed regulatory criteria for FDA approval

2013 · External reference

Review of drugs approved via the 505(b)(2) pathway: uncovering drug development trends and regulatory requirements

10.1007/s43441-019-00036-y · 2020 · External reference

Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: a single-arm, multi-center study

2023 · External reference

Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: a retrospective cohort study

10.1111/bcp.16243 · 2025 · External reference

Biosimilarity assessment of the biosimilar teriparatide candidate and the reference drug in healthy subjects

10.1002/cpdd.1221 · 2023 · External reference

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women

10.1007/s00198-022-06573-x · 2023 · External reference

10.1007/s00198-024-07208-z

10.1007/s00198-024-07208-z · 2024 · External reference

Biosimilar cost savings in the United States: initial experience and future potential

2018 · External reference

Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial

10.1001/jama.2016.11136 · 2016 · External reference